Geoffrey has over thirty years experience in healthcare. During the past fifteen years Geoffrey has established a successful track record in the role of Chairman or NED during his association with more than 42 international healthcare companies. He has significant experience of corporate governance in quoted companies and also chairs the Audit committees of public companies in Germany, the UK and US. Over the last fifteen years he has established credibility with European and US investment bankers, analysts and financial institutions and has a unique blend of experience, having worked in industry, public and private companies, venture capital and an exposure to fund management. He has had direct involvement in the process of taking a number of companies public, the last one being XLTechgroup where he was asked to join the Board as Chairman immediately prior to its float in London in September 2004.

Dr. Andrew Muddle co-founded MedPharm in August 1999 and is the Chief Executive Officer
Dr. Muddle has spent 19 years in the pharmaceutical industry in the drug delivery area and worked for a number of companies of varying sizes. At PowderJect Pharmaceuticals plc, he was Technical Director (Pharmaceutical Development) with responsibility for pharmaceutical sciences, pre-clinical and clinical functions. He held this position for three and a half years and made a major contribution in the early development of the company and was pivotal in the IPO in 1997. Dr. Muddle has managed development projects through to commercialization of several transdermal patch products. Prior to this he has also held technical positions with drug delivery companies such as the Elan Corporation, Ethical Pharmaceuticals Ltd (U.K.), Controlled Therapeutics (Scotland) and Ciba-Geigy (now Novartis).

Prof. Marc Brown is a co-founder of MedPharm and Chief Scientific Officer. Prof. Brown was recently appointed as Professor of Pharmaceutics in the School of Pharmacy, University of Hertfordshire after spending nearly 15 years as an academic in the Pharmacy Department, King's College London. At KCL, he was previously, with Prof. Marriott, co-director of the Medicines Research and Development Centre. His research interests lie mainly in drug delivery to the skin nail and airways and he has 80 publications and ten patents describing his work. Prof. Brown has previously worked for Canadian drug delivery company Hyal as Director of Pharmaceutical and Analytical Development where he managed the development and approval of several topical formulations for the North American and European markets.

Katie is MedPharm’s part time Finance Director. Katie is a Chartered Accountant and qualified with KPMG in 1992. She is also a student member of the Institute of Chartered Secretaries and Administrators. Katie spent six years as Vice President R & D Finance and Group Treasurer at PowderJect Pharmaceuticals plc.

Katie was integral to a successful IPO with PowderJect Pharmaceuticals in 1997 and had significant involvement in subsequent fund raising, acquisitions, divestments and reorganizations. Katie now supports a number of small growing biotech companies in the capacity of Finance Director and Company Secretary.